Brief: Elicera Therapeutics Receives EU Funding
June 2 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* RECEIVES 2.5 MILLION EUROS IN EU FUNDING TO FULLY FINANCE
A
CLINICAL PHASE I/II-TRIAL WITH ITS CAR T-CELL THERAPY, ELC-301
* GRANT IS SUFFICIENT TO FULLY FUND ELICERA'S PLANNED
CLINICAL
PHASE I/II-STUDY EVALUATING ITS CAR T-CELL THERAPY ELC-301 IN
TREATMENT OF B-CELL LYMPHOMA
Source text for Eikon: ID:nWkrY3tpm
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent